Illumina, Inc. ILMN
Composite 59/100; the shares have moved about 42% annualised. Names that move more contribute more risk for the same amount invested, and our composite reflects how strong the evidence for this one is right now.
Valuation ranks 20/100 — a strong mark against it.
Momentum ranks 82/100 — a strong point in its favour. Quality ranks 79/100 — a strong point in its favour. Balance-sheet strength ranks 70/100 — a moderate point in its favour.
Valuation ranks 20/100 — a strong mark against it. Growth ranks 41/100 — a slight mark against it.
What the company does Illumina provides sequencing and array-based solutions for genetic and genomic analysis, serving research centers, hospitals, and biotech firms. Its products include instruments, consumables, and services like whole-genome sequencing and noninvasive prenatal testing.
Key financials ILMN reports strong profitability with ROE 33.8%, ROA 8.7%, and net margins 19.4%. Revenue and EPS growth are 4.8% and 6.1%, respectively, while debt/equity stands at 0.95 and interest coverage is 11.61.
Stock health The stock shows strong momentum with 12-month returns of 88.66% and RSI(14) at 67.50. Quality scores are high (73.4), but valuation metrics (P/E 35.81, EV/EBITDA 21.49) are elevated.
Price vs fair value The stock trades at a **PREMIUM of 59.50%** to our fair-value estimate and a **PREMIUM of 15.88%** to the 12-month analyst target. - Q2 2026 earnings beat and revenue growth cited as drivers (Zacks, StockStory). - Full-year outlook slightly exceeded expectations (StockStory). - Collaboration with Eli Lilly for AI drug discovery highlighted (Simply Wall St). - Recent earnings call emphasized strong clinical growth (GuruFocus, Motley Fool).
Looking forward Analysts cite clinical growth and AI partnerships as tailwinds, but valuation remains a key overhang. Forward P/E of 37.04 reflects high expectations. Momentum (85.0) and quality (73.4) scores remain supportive.
This is not investment advice. Sideravia provides automated, data-driven analysis for information and education only. Nothing on this page is a personal recommendation or an invitation to buy or sell any security, and it does not consider your objectives or financial situation. Assessments are generated by rules applied uniformly to every covered stock — how our scores work.
Data as of 2026-09-03, compiled from third-party sources; errors and delays are possible and figures are not warranted. Investing puts your capital at risk; past performance does not predict future results. We publish our full track record, including the calls that lost, and our conflicts of interest.